Menu Close

Author: WorkCompAcademy

DWC Posts Adjustments to OMFS/DMEPOS Fees

The Division of Workers’ Compensation (DWC) has posted an order adjusting the Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) section of the Official Medical Fee Schedule to conform to the third quarter 2016 changes in the Medicare payment system, as required by Labor Code section 5307.1.

The update includes all changes identified in Center for Medicare and Medicaid Services Change Request (CR) number 9642.

The CMS issues instructions for implementing and/or updating DMEPOS payment amounts on a semiannual basis (January and July), with quarterly updates as necessary (April and October). Updates to the codes adjusted using information from the competitive bidding program (CBP) will be made each time the payment amounts under the CBPs are adjusted or additional CBPs or payment amounts are established for the items and services. When applicable, these updates will be included in the quarterly DMEPOS change request instructions. The DMEPOS fee schedule is provided to DME MACs, the Pricing, Data Analysis and Coding Contractor (PDAC), Part A MACs, HHH MACs and Part B MACs via CMS’ mainframe telecommunication system.

The DMEPOS fee schedules are calculated by CMS. A separate DMEPOS Fee Schedule file is released to the intermediaries, regional home health intermediaries, Railroad Retirement Board (RRB), Indian Health Service and United Mine Workers. The fee schedule for parenteral and enteral nutrition (PEN) is released to the PDAC and DME MACs in a separate file. These files are also available through the CMS Website for interested parties like the State Medicaid agencies and managed care organizations.

The order, effective for services on or after July 1, 2016, adopts the Medicare DMEPOS quarterly update for calendar year 2016.

The order adopting the Official Medical Fee Schedule adjustment is posted online

Federal Judge Disqualifies SCIF Attorneys in Drobot RICO Case

A federal judge reaffirmed the disqualification of the State Fund attorneys, Hueston Hennigan, from the $160 million medical fraud case it brought three years ago on behalf of its now-former client in the massive racketeering case.

The 75-page ruling filed last week details how the concurrent representation of the State Fund and at the same time defends Paul Randall in his criminal case betrayed both parties, created “incestuous” twists (Pg. 37) and was anathema to the adversarial legal system.

The defendants in the SCIF civil litigation that started in 2013 stand accused of conspiring to defraud the State Compensation Insurance Fund by submitting fraudulent insurance bills and providing or receiving illegal kickbacks. The litigation arising out of this purported scheme involves dozens of defendants, two civil suits and a criminal suit, and well over a thousand filings spanning three years and three dockets. SCIF was at first represented by law the firm of Irell & Manella LLP. In January 2015, John Hueston and Brian Hennigan, along with thirty or so other lawyers, left Irell & Manella to form Hueston Hennigan. There Hueston and other lawyers continued to represent SCIF.

The U.S. Department of Justice filed criminal charges against some of these defendants for the same kickback scheme. One of them, Paul Richard Randall, 56, of Orange, California, a health care marketer previously affiliated with Pacific Hospital and Tri-City Regional Medical Center in Hawaiian Gardens, pleaded guilty on April 16, 2012 to conspiracy to commit mail fraud. Randall has not been sentenced yet.

The most recent round of motions in the SCIF RICO case focused on the question about whether a law firm could represent a criminal and his victim. One of the civil defendants, Dr. Lokesh Tantuwaya, M.D., discovered that Hueston Hennigan had represented Randall in one of the criminal cases and possibly a related civil case. Tantuwaya filed the most recent motion for disqualification of the firm.

After considering about a thousand pages of documents and more than four hours of oral argument on this disqualification issue, “the Court confirmed that disqualification was appropriate and necessary here.” The ruling pointed out the following rationale.

“Being a defendant – particularly a criminal one – can be lonely. As a society, we don’t require a defendant’s friends to stand by the defendant. We don’t require a defendant’s parents to stand by the defendant. We don’t require a defendant’s children to stand by the defendant. We don’t even require a defendant’s spouse to stand by the defendant, though that spouse is often someone who took an oath to do so.”

“But a lawyer is different. Representing a client creates an unshakable loyalty that can still persist when bonds of friendship and family fail. There’s a practical reason for this. A lawyer needs to know the worst facts to give clients the best advice. Clients can’t feel comfortable providing such candor unless they know their lawyer is absolutely committed to advancing the clients’ interests and advocating against the conflicting interests of others. Though the rest of the world may be united against them, clients need to know that at least their lawyer will reliably remain in their corner, even in the face of great temptation.”

“The importance and impact of loyalty in the attorney-client relationship extends beyond the client and counsel, to courts too. Judges are often confronted with important issues and difficult disputes. Under our system of law, judges rely on adversarial advocates to help ensure that courts reach the right results in these situations. Adversarial advocacy assumes that lawyers are fiercely loyal in representing their clients. If that loyalty doesn’t exist, the engine of our legal system can’t run. Justice can’t be administered.”

And finally the court made note of the fact that this “disqualification likely caused and will continue to cause grief to lots of people. Of course there’s SCIF and Hueston Hennigan. SCIF is left trying to get its new counsel up to speed on about three years of litigation involving dozens of defendants and opposing attorneys, while Hueston Hennigan must drop a likely lucrative matter from its billing. But there are others too. Randall is left with uncertainty about his legal representation while he has to prepare for a life-altering sentencing hearing. And the Hueston Hennigan attorneys – in particular those in the trenches, who worked passionately on this case for years and who had nothing to do with the representation decisions – have had the rug pulled out from under them, and have had to drop a case they likely lived with for years. Even the civil defendants and their lawyers will have to do some shuffling to deal with the new folks on the other side of the courtroom.”

Hueston Hennigan spokeswoman Lisa Richardson said in a statement quoted by the Los Angeles Business Journal that outside experts have consistently validated the firm’s actions in dealing with the conflict. “After the court’s tentative ruling, State Fund obtained the guidance and opinions of two nationally recognized experts and a former state bar official; each has opined that conflicts were handled well within the ethical rules,” Richardson said. “No experts in this case have opined otherwise.”

WCIRB Submits January 1, 2017 Regulatory Filing

The WCIRB submitted to the California Department of Insurance a January 1, 2017 Regulatory Filing that proposes changes to the Insurance Commissioner’s regulations contained in the California Workers’ Compensation Uniform Statistical Reporting Plan – 1995 (Uniform Statistical Reporting Plan), the California Workers’ Compensation Experience Rating Plan – 1995 (Experience Rating Plan), and the Miscellaneous Regulations for the Recording and Reporting of Data – 1995.

Among the proposed amendments to the Uniform Statistical Rating Plan are changes to the Standard Classification System and to the definition of medical-only claims to specify that all claims, including first aid claims, must be reported to the WCIRB.

The Filing also contains proposed amendments to the Experience Rating Plan including changes to the experience modification worksheet to show the primary threshold and revised tables to include proposed 2017 experience rating values based on the variable split plan that was approved in last year’s Regulatory Filing to be effective January 1, 2017. These proposed experience rating values include primary thresholds by employer size, D-Ratios for each primary threshold and each classification, expected loss rates by classification, and credibility primary and credibility excess values.  

The complete Filing containing all of the WCIRB’s proposed changes and any related documents are available in the Publications and Filings section of the WCIRB website. The WCIRB website will be updated to provide a copy of the Notice of Proposed Action and Notice of Public Comment once it is received from the CDI.

This Filing does not contain proposed changes to the advisory pure premium rates. The WCIRB anticipates submitting the January 1, 2017 Pure Premium Rate Filing this August.

Feds Lose First “Yates Memo” Criminal Trial Against Drugmaker President

Like many before it, this year has been one to watch in government health care fraud enforcement efforts. In September 2015, the Department of Justice (DOJ) released the “Yates Memo,” which reaffirmed the government’s commitment to investigating and prosecuting culpable individuals in cases involving suspected corporate fraud.

While the Yates Memo was not specific to health care companies, the health care industry was anxious to see how the government’s strong re-commitment to holding individuals accountable for corporate wrongdoing would play out given its aggressive pursuit of health care fraudsters. Perhaps the best known test case came when the government announced in October 2015 that it had arrested W. Carl Reichel, the former president of Warner Chilcott, a subsidiary of a pharmaceutical manufacturer. Reichel was indicted and charged with a single count of conspiring to pay kickbacks to physicians in violation of the Anti-Kickback Statute (AKS).

According to the story in the National Law Review, the DOJ announced the Reichel indictment on the same day that it released a statement reporting that the company had agreed to plead guilty to a felony charge of health care fraud. This plea agreement was part of a global settlement under which Warner Chilcott would pay $125 million to resolve criminal and civil liability arising from certain marketing activities. The government held up Reichel’s personal indictment as an example of its commitment to not only holding companies accountable, but also “identif[ying] and charg[ing] corporate officials responsible for the fraud.”

The government’s case did not go as anticipated and last week, given that a federal jury acquitted Reichel.

On October 28, 2015, a grand jury in the U.S. District Court for the District of Massachusetts returned an indictment charging Reichel with a single count of conspiring to pay kickbacks to physicians to induce them to order Warner Chilcott drugs.The alleged kickbacks were in the form of free dinners, “speaker fees” paid for speeches never given, and free food and drinks for physicians’ staff members who filled out prior authorizations for the company’s drugs. The indictment further alleged that Reichel, as the President of Warner Chilcott’s pharmaceuticals division, along with other senior executives, gave sales representatives nearly unlimited expense accounts to take physicians and their spouses out for bi-weekly “medical education programs,” which were in fact just free, expensive dinners with no educational component. Physicians who were especially high orderers were paid speaker fees of $600-$1,200 to speak at these medical educational programs, but, in reality, did not give any clinical lectures.

In return for these dinners and speaking fees, Reichel was alleged to have instructed sales representatives to follow up with the physicians who attended the dinners and ensure that they ordered a sufficient number of Warner Chilcott drugs. Physicians who did not do so were no longer invited to dinners or were terminated as “speakers” until their prescribing habits changed.

For months, the health care industry watched as Reichel battled with DOJ attorneys to gain additional information regarding the facts on which his indictment was based (e.g., the names of his alleged co-conspirators), requested information about plea agreements with potential witnesses against him, attempted to limit the evidence that would be used against him, and challenged the government’s proposed jury instructions as being too vague on the scienter required to prove an AKS violation. On May 23, 2016, the case went to trial and on June 17, 2016 – after two days of deliberations – the jury acquitted Reichel.

During the trial, the government presented evidence that under Reichel’s oversight, Warner Chilcott paid for 200,000 dinner tabs, provided clients with $100 steaks and sailing trips to Rhode Island, and paid $25 million in speaker fees. To make its case, the government relied upon testimony from members of Warner Chilcott’s sales staff, some of whom had entered into plea agreements with the government, expecting lesser sentences in exchange for their testimony against Reichel. Reichel, in turn, argued that the only quid pro quo at issue was the government’s deals with these witnesses, whom his lawyers characterized as admitted felons who ignored company policies.

Based on its verdict, it seems that the jurors may not have been convinced that the dinners and other payments to physicians and their staff were sufficiently tied to past or future prescriptions to constitute an AKS violation. Clearly the government did not meet its burden to prove that Reichel knew that his conduct was illegal. Whatever the reason, the Reichel acquittal may be an early sign that despite the government’s renewed commitment to prosecuting individuals, juries may be setting a higher bar for holding individuals responsible for corporate wrongdoing.

3D Printer Used to Create Replacement Joint Cartilage

Strands of cow cartilage substitute for ink in a 3D bioprinting process that may one day create cartilage patches for worn out joints, according to a team of engineers and their story published in Science Daily. “Our goal is to create tissue that can be used to replace large amounts of worn out tissue or design patches,” said Ibrahim T. Ozbolat, associate professor of engineering science and mechanics at the Pennsylvania State University. He specializes in manufacturing and tissue engineering, with numerous articles published in the context of bioprinting..

Cartilage is a good tissue to target for scale-up bioprinting because it is made up of only one cell type and has no blood vessels within the tissue. It is also a tissue that cannot repair itself. Once cartilage is damaged, it remains damaged.

Previous attempts at growing cartilage began with cells embedded in a hydrogel — a substance composed of polymer chains and about 90 percent water — that is used as a scaffold to grow the tissue.

“Hydrogels don’t allow cells to grow as normal,” said Ozbolat, who is also a member of the Penn State Huck Institutes of the Life Sciences. “The hydrogel confines the cells and doesn’t allow them to communicate as they do in native tissues.”

This leads to tissues that do not have sufficient mechanical integrity. Degradation of the hydrogel also can produce toxic compounds that are detrimental to cell growth.

Ozbolat and his research team developed a method to produce larger scale tissues without using a scaffold. They create a tiny — from 3 to 5 one hundredths of an inch in diameter — tube made of alginate, an algae extract. They inject cartilage cells into the tube and allow them to grow for about a week and adhere to each other. Because cells do not stick to alginate, they can remove the tube and are left with a strand of cartilage. The researchers reported their results in the current issue of Scientific Reports.

The cartilage strand substitutes for ink in the 3D printing process. Using a specially designed prototype nozzle that can hold and feed the cartilage strand, the 3D printer lays down rows of cartilage strands in any pattern the researchers choose. After about half an hour, the cartilage patch self-adheres enough to move to a petri dish. The researchers put the patch in nutrient media to allow it to further integrate into a single piece of tissue. Eventually the strands fully attach and fuse together.

“We can manufacture the strands in any length we want,” said Ozbolat. “Because there is no scaffolding, the process of printing the cartilage is scalable, so the patches can be made bigger as well. We can mimic real articular cartilage by printing strands vertically and then horizontally to mimic the natural architecture.”

The artificial cartilage produced by the team is very similar to native cow cartilage. However, the mechanical properties are inferior to those of natural cartilage, but better than the cartilage that is made using hydrogel scaffolding. Natural cartilage forms with pressure from the joints, and Ozbolat thinks that mechanical pressure on the artificial cartilage will improve the mechanical properties.

If this process is eventually applied to human cartilage, each individual treated would probably have to supply their own source material to avoid tissue rejection. The source could be existing cartilage or stem cells differentiated into cartilage cells.

Employers Fear Proposed Anthem-Cigna Merger

As questions mount over whether health insurer Anthem Inc’s proposed $48 billion purchase of Cigna Corp will win U.S. antitrust approval, an exclusive analysis produced for Reuters suggests the merger could lead to higher costs for large companies offering workplace medical benefits.

More than 154 million people receive health benefits through employers, many of them large national corporations. The large employer market is a top concern for U.S. Department of Justice regulators reviewing the Anthem deal, company officials say. The government could block a deal if it finds evidence it would drive up the cost of such coverage.

Anthem and Cigna, the nation’s No. 2 and No. 5 health insurers, are among a handful of carriers selling national coverage plans to employers with thousands of workers across many states.

Anthem has said the added heft will work for employers, not against them. A bigger Anthem, it emphasizes, could drive better deals from doctors and hospitals and pass savings onto these customers. In addition, Anthem has argued that there still will be plenty of competition: large employers pit smaller, local insurers’ bids against those of large national carriers in regional markets. Anthem officials told an investor conference last month that many employers include health plans from several smaller insurers to cover far-flung employees.

But an Aon Hewitt analysis of benefits data for Reuters found that a majority of large employers buy worker health benefits from just one or two insurers.Among 75 companies representing a cross-section of industries, 54 percent used a single insurer and 26 percent used two. Aon Hewitt, a unit of Aon Plc which helps employers select their benefit plans, based its analysis on data from over 400 customers that participate in healthcare cost research.

Spokeswoman Maurissa Kanter said Aon Hewitt did not conclude “whether or not carrier consolidation would be a competitive issue that could lead to higher prices for employers.” She also said that the data did not “support an argument for or against market consolidation.”

Several human resources directors from large corporations also told Reuters they review potential benefits contracts from only the biggest insurers, rather than regional players. UnitedHealth Group, Anthem, Aetna Inc and Cigna are the only national players in the employer health insurance market.

It is less efficient for companies to hire multiple regional insurers, and the merger could allow the few remaining national insurers to raise their rates, said Peter Carstensen, an antitrust expert and professor emeritus at the University of Wisconsin Law School. “The Aon Hewitt data on its face is bad for the deal and hurts their chances of getting approval,” Carstensen said.

A Justice Department official declined to comment on its review of the deal. It is also considering Aetna’s proposed $34 billion purchase of Humana Inc. If both acquisitions were approved, it would result in an unprecedented consolidation of the top insurers, from five to three.

Anthem has said that buying Cigna would help it drive deeper discounts from hospitals and doctors, holding down the price of medical coverage. “What the Department of Justice will see is that we are going to bring a better focus on managing the cost of care,” Anthem Chief Executive Joseph Swedish told an investor conference last month.

But at least some large U.S. employers fear they will face higher prices if the deal goes through, according to Wall Street analysts. Concerned employers include Detroit automakers, according to a person familiar with the industry’s position.

Other employers found merit in Anthem’s assertion that the deal could benefit customers by eliminating overhead. “There is some chance that consolidation could lower some of those costs,” said Michael D’Ambrose, chief human resources officer for Archer Daniels Midland Co (ADM.N), which buys coverage from Anthem and other Blue Cross Blue Shield plans.

The deal has raised opposition from leading medical groups, California’s insurance commissioner and Democratic lawmakers.

Unlicensed Insurance Broker Arrested for Selling Fake Policies

Robert Meseer, 63, of Westminster, was arrested by California Department of Insurance investigators on 32 felony counts of grand theft, insurance fraud, and forgery after acting as an insurance agent to allegedly steal more than $140,000 from several business owners.

Evidence revealed Meseer, doing business as MRM Insurance, began illegally managing MRM Insurance after a relative’s license expired in 2009. The relative had been operating the agency, which gave Meseer access to client files and allowed him to implement various schemes to bilk premiums from unsuspecting policyholders.

“Meseer’s alleged criminal acts exposed victims to thousands of dollars of financial risk and loss,” said Commissioner Dave Jones. “It is important for consumers and businesses to check on the license status of any agent in order to protect themselves and their finances.”

After receiving a referral from a business owner who discovered Meseer had issued them a bogus insurance certificate listing a nonexistent insurance company, the Department of Insurance Investigation Division launched an investigation. Additional evidence revealed numerous alleged violations by Meseer, including issuing bogus insurance documents, overcharging several times the amount of the premium, giving inflated billings, not disclosing the true cost of coverage to customers, renewing policies without forwarding’ premium payments, and even soliciting new insurance business, all without a proper license.

Meseer was booked into Orange County Jail and bail is set at $100,000. The Orange County District Attorney’s office is prosecuting this case.

USC Study Finds Wholesale Abandonment of Cyber Security in Hospitals

Hospitals are pretty hygienic places — except when it comes to passwords.

That’s the conclusion of a recent study by researchers at Dartmouth College, the University of Pennsylvania and USC, which found that efforts to circumvent password protections are “endemic” in healthcare environments and mostly go unnoticed by hospital IT staff.

The researchers interviewed medical personnel in their workplace settings–nurses, doctors, chief medical officers, chief medical information officers, cybersecurity experts, CIOs, IT workers, everyday users, and managers–to obtain their perceptions of computer security rules. They collected reports from medical discussion lists and other literature. In addition, they shadowed many clinicians as they conducted their work.

The report describes what can only be described as wholesale abandonment of security best practices at hospitals and other clinical environments — with the bad behavior being driven by necessity rather than malice.

And this is certainly not good news for payers of health care services such as workers’ compensation claim administrators. Identity theft is a centerpiece of health care fraud schemes. The health/medical sector has accounted for the highest percent (42.5% in 2014) of total hackings of any industry, according to the Identity Theft Resource Center.

“Cyber security efforts in healthcare settings increasingly confront workarounds and evasions by clinicians and employees who are just trying to do their work in the face of often onerous and irrational computer security rules. These are not terrorists or black hat hackers, but rather clinicians trying to use the computer system for conventional healthcare activities. These “evaders” acknowledge that effective security controls are, at some level, important – especially the case of an essential service, such as healthcare. As we observed, earlier, without such tools, the enterprise cannot protect against adversarial cyber action. Unfortunately, all too often, with these tools, clinicians cannot do their job – and the medical mission trumps the security mission.”

“In hospital after hospital and clinic after clinic, we find users write down passwords everywhere,” the report reads. “Sticky notes form sticky stalagmites on medical devices and in medication preparation rooms. We’ve observed entire hospital units share a password to a medical device, where the password is taped onto the device.”

“We found emergency room supply rooms with locked doors where the lock code was written on the door — no one wanted to prevent a clinician from obtaining emergency supplies because they didn’t remember the code.”

“We find, in fact, that workarounds to cyber security are the norm, rather than the exception. They not only go unpunished, they go unnoticed in most settings – and often are taught as correct practice. In rare exceptions, when the workarounds become obvious to leaders – such as a security breach involving a patient’s record – there may be repercussions. These common forms of ignorance, or willful blindness, or incomprehension allow organizations to continue to deploy security that doesn’t work.”

Competing priorities of clinical staff and information technology staff bear much of the blame. Specifically: IT staff and management are often focused on regulatory compliance and securing healthcare environments. They are excoriated for lapses in security that result in the theft or loss of data.

Clinical staff, on the other hand, are focused on patient care and ensuring good health outcomes, said Ross Koppel, one of the authors of the report, who told The Security Ledger. Those two competing goals often clash. “IT want to be good guys. They’re not out to make life miserable for the clinical staff, but they often do,” he said.

London-based European Medicines Agency (EMA) in Turmoil After Brexit Vote.

Britain’s vote yesterday to leave the European Union spells regulatory uncertainty for drug companies, with the London-based European Medicines Agency (EMA), which approves treatments for all EU countries, expected to have to relocate.

The European Medicines Agency (EMA) is a European Union agency for the evaluation of medicinal products. Prior to 2004, it was known as the European Agency for the Evaluation of Medicinal Products (EMEA).

Roughly parallel to the drug part of the U.S. Food and Drug Administration (FDA), but without centralization, the EMA was set up in 1995 with funding from the European Union and the pharmaceutical industry, as well as indirect subsidy from member states, in an attempt to harmonize (but not replace) the work of existing national medicine regulatory bodies.

The hope was that this plan would not only reduce the €350 million annual cost drug companies incurred by having to win separate approvals from each member state but also that it would eliminate the protectionist tendencies of sovereign states unwilling to approve new drugs that might compete with those already produced by domestic drug companies. The EU is currently the source of about one-third of the new drugs brought onto the world market each year.

According to the report in Reuters Health, the association of Germany’s pharmaceuticals industry said that EMA would need to move to a city within the EU, bringing administrative headaches for companies.

Britain’s biggest drugmaker, GlaxoSmithKline, said the exit vote “creates uncertainty and potentially complexity for us in the future”, though the impact on its global business would be small, while the UK pharma trade association warned of challenges to future investment, research and jobs.

Industry executives fear upheaval at the EMA could snarl the EU’s drug approval process and Britain may have to develop its own domestic regulatory system, leading to further confusion.

Although Britain could continue to take part in the EMA system if it remains in the European Economic Area, like Norway, many of those supporting its exit from the EU oppose that option.

As a result, British patients could move to the back of the queue for new medicines as companies prioritize the larger EU market, and some medicines could be left in regulatory limbo.

The EMA, with a full-time staff of more than 600, is the largest EU body in Britain and has overseen pan-European drug approvals since 1995 from its headquarters tucked away among global banks in London’s Canary Wharf.

An EMA spokeswoman said it was premature to comment on its future. “It is too early to foresee the implications of this decision and at this stage we are waiting for further guidance from the European Commission,” she said.

Drug companies and healthcare officials in Sweden, Denmark, Italy and Germany have all expressed interest in hosting the EMA instead of London, since firms in these countries are keen to be located close to the region’s key regulator.

Court of Appeal Says Late IMR Decision is Still Valid

The WCAB has issued a number of panel level decisions eroding the jurisdiction of the UR and IMR process for technical mistakes that were claimed to have “invalidated” the process and the UR/IMR finding.  These cases  favored handing the issue of appropriate medical treatment over to the WCJ to decide. As a result UR/IMR seemed to be subjected to a slow death by a thousand such cuts. However, the trend of erosion of UR/IMR jurisdiction may have suffered a setback at the hands of a new Court of Appeal published decision.

Dorothy Margaris suffered a work-related injury to her left foot and lumbar spine while employed by the California Highway Patrol. The State Compensation Insurance Fund is the adjusting agent for this claim.

On October 16, 2014, her treating physician submitted a request for authorization of medical treatment to SCIF proposing to treat applicant with a lumbar epidural injection. On October 21, 2014, SCIF denied the request.

Applicant timely requested independent medical review. On November 26, 2014, SCIF sent the necessary medical records to Maximus Federal Services, Inc. On January 8, 2015, Maximus issued its IMR determination, upholding SCIF’s denial of the proposed medical treatment. The IMR determination became the final determination of the director as a matter of law. (§ 4610.6, subd. (g).)

Margaris appealed the IMR determination to the appeals board (§ 5300), which directed the matter to an administrative law judge for a hearing (§ 5310). She argued argued that the IMR determination was invalid because Maximus failed to issue it within the 30-day time period provided by section 4610.6, subdivision (d), and the applicable regulation (Cal. Code Regs., tit. 8, § 9792.10.6, subd. (g)). The judge agreed the IMR determination was issued 13 days late, but nevertheless found the determination was valid and binding on the parties, concluding that an untimely IMR determination “does not confer jurisdiction on the [workers’ compensation judge] to decide any medical treatment issues.”

In response to her petition for reconsideration, a majority of the three-member panel agreed with applicant and went on to find, contrary to the IMR determination, that the proposed treatment was supported by substantial medical evidence and was consistent with the treatment schedule promulgated by the director. One member of the panel dissented, and would have found that the IMR determination, though untimely, was valid and binding on the parties.

The Court of Appeal disagreed with the WCAB and reversed in the published case of California Highway Patrol and SCIF v WCAB (Margaris).

The 30-day time limit in section 4610.6, subdivision (d), is directory and, accordingly, an untimely IMR determination is valid and binding upon the parties as the final determination of the director. The Court of Appeal interpretation of the statute in this manner is consistent with long-standing case law regarding the mandatory-directory dichotomy, and implements the Legislature’s stated policy that decisions regarding the necessity and appropriateness of medical treatment should be made by doctors, not judges.

Generally, time limits applicable to government action are deemed to be directory unless the Legislature clearly expresses a contrary intent. By creating IMR, a system in which “medical professionals ultimately determine the necessity of requested treatment,” the Legislature intended to “further[] the social policy of this state in reference to using evidence-based medicine to provide injured workers with the highest quality of medical care.” Further, the Legislature observed that the prior system of dispute resolution, i.e., the “process of appointing qualified medical evaluators to examine patients and resolve treatment disputes,” was not only costly and time-consuming, but “it prolong[ed] disputes and cause[d] delays in medical treatment for injured workers.” (Stats. 2012, ch. 363, § 1(f).)

“The Legislature intended to remove the authority to make decisions about medical necessity of proposed treatment for injured workers from the appeals board and place it in the hands of independent, unbiased medical professionals. Construing section 4610.6, subdivision (d), as directory best furthers the Legislature’s intent in this regard.”